I agree with Drano"s post # 68134 that if Brilacid

I agree with Drano"s post # 68134 that if Brilacidin becomes the standard of care (SOC), most doctors will make sure they can administer it. ”If Brilacidin can save the world by having a drug that stops this virus in its tracks, no matter what the mutation is, no one is going to balk at administering IVs.”

I also agree with Pete’s post # 68131 that “It's cost, ease of storage and delivery, and safety profile should make it the TOTAL treatment for any stage of CV19.”

Also per Ultimate’s post #68091 Dr. Fauci stated regarding CV19 therapeutics, “We are challenged with and we have to do better with” and “but the real goal is to get antiviral drugs that directly act against the virus itself.”

IMO a success in the upcoming B-CV19 human trial will position Brilacidin as the first antiviral that has virucidal properties (kills the CV19 virus) and that Brilacidin will become the new SOC for CV19. Note that an article published today from USA Today regarding Lily’s Monoclonal Antibody Cocktail which is similar to the Regeneron drug “once hospitalized with COVID-19, the drug does nothing to help, a Lilly study has shown." We also know that that the current therapeutic SOC for CV19 is remdesivir which has shown no improvement in CV19 mortality rates, has minimal effectiveness in reducing the viral load and is not as safe as Brilacidin.

There is an awareness that both effective and safe therapeutics are needed to compliment a vaccine rollout to effectively combat this pandemic. The bar for safe and effective CV19 treatments is set very low IMO and there will be huge worldwide demand for Brilacidin once this upcoming human trial is successfully concluded.

Once success is proven in the upcoming trial I believe Brilacidin will become the new SOC for CV19. I expect that numerous funding opportunities will be presented to Leo from both the U.S. and other government agencies as well as a strong interest from Big Pharma who will be aggressively positioning to partner via licensing and distribution. Once funding is in place I would expect that many opportunities will be available to further advance the science and market penetration including the following statement from the IPIX 10-Q dated 11/16/20 page 28:

“Partnering opportunities with industry and academic partners are ongoing regarding the COVID-19 program. The Company through discussions with industry, academic consultants, and potential partners will also explore investigation of treatment with Brilacidin by inhaled administration for the prevention of COVID-19 infection.”

There are exciting times ahead for IPIX investors. Worldwide demand from millions of people require a safe and effective treatment for this pandemic and future pandemics that will hopefully soon become available.